ClinicalTrials.gg
RecruitingNCT04804943Updated Jul 9, 2024

Pilot Clinical Study of NOA-001 for ARDS (Acute Respiratory Distress Syndrome)

An interventional study of NOA-001 in Acute Respiratory Distress Syndrome, sponsored by Toray Industries, Inc. Recruiting at 1 site in Japan. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2024-07-09.

Sponsored by Toray Industries, Inc · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Study summary

The primary object of this clinical study is to investigate the efficacy and the safety of NOA-001 in patients with ARDS (ARDS caused by Non-COVID-19 or COVID-19).

Read the detailed description

(ARDS caused by Non-COVID-19 cohort): The objectives of this clinical study is to investigate the efficacy and safety of NOA-001 in patients with ARDS caused by Non-COVID-19. The number of patients enrolled is 30 (20 patients in the NOA-001 group and 10 patients in the standard therapy group).

(ARDS caused by COVID-19 cohort): The objectives of this clinical study is to investigate the efficacy and the safety of NOA-001 in patients with ARDS caused by COVID-19. The number of patients enrolled is 15 (in the NOA-001 group only).

02

Conditions studied

  • Acute Respiratory Distress Syndrome

Keywords

  • COVID-19
  • Diffuse Alveolar Damage
  • DAD
  • Acute Respiratory Distress Syndrome
  • ARDS
  • NOA-001
  • Hemoperfusion
03

In context

Respiratory Distress Syndrome

1,388 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

This study's planned enrollment of 45 is below the median of 60 across 823 interventional studies indexed under Respiratory Distress Syndrome.

Browse Respiratory Distress Syndrome studies →

Lead sponsor

Toray Industries, Inc is the lead sponsor of 17 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

(ARDS caused by Non-COVID-19 cohort)

Inclusion Criteria:

At

  1. Patients with ARDS confirmed by the Berlin definition based on the following diagnostic criteria (a)-(d):

    1. Patients within 7 days from invasion or exacerbation of respiratory symptoms or acute onset of ARDS.
    2. Patients with respiratory failure not fully explained by cardiac failure or fluid overload; Need objective assessment (e. g., echo-cardiography) to exclude hydrostatic edema if no risk factor present
    3. Patients with bilateral opacities not fully explained by effusions, lobar/ lung collapse, or nodules on chest X-ray or CT scan
    4. Patients with PaO2/ FiO2 ratio ≤ 300 mmHg (PEEP ≥ 5 cmH2O)
  2. Patients who are intubated and mechanically ventilated
  3. Patients who can be enrolled in the study within 96 hours after initiation of mechanical ventilation
  4. Patients aged ≥ 16 years at informed consent (Signed informed consent form from legally acceptable representative must be available if patient is aged \< 20 years)

At Enrollment

  1. Patients with PaO2/ FiO2 ratio ≥ 50 mmHg and ≤ 200 mmHg (PEEP ≥ 5 cmH2O)
  2. Patients with bilateral opacities not fully explained by effusions, lobar/ lung collapse, or nodules on CT scan within 48 hours before enrollment
  3. Patients who are intubated and mechanically ventilated
  4. Patients who can be enrolled in the study within 96 hours after initiation of mechanical ventilation

Exclusion Criteria:

At Informed Consent

  1. Patients who are considered to be extremely unlikely to withdraw from mechanical ventilation
  2. Patients who are treated with ECMO or HFOV
  3. Patients with renal dialysis therapy for chronic renal failure
  4. Patients with congestive heart failure ( class IV)
  5. Patients with acuter left ventricular failure
  6. Patients with liver failure ( grade C)
  7. Patients who have burns in excess of 15% total body surface area
  8. Patients after resuscitation from cardiac arrest
  9. Patients with a history of to the anticoagulants (Heparin or Nafamostat mesylate)
  10. Patients who have received cytapheresis, blood purification therapy with cytokine adsorbing devices or endotoxin removal therapy within 7 days prior to informed consent
  11. Patients with pregnancy or lactating
  12. Patients tested positive for COVID-19

At Enrollment

  1. Patients who are considered to be extremely unlikely to withdraw from mechanical ventilation
  2. Patients who are treated with ECMO or HFOV after obtaining informed consent prior to enrollment
  3. Patients with count ≤ 50,000 /mm3 by the latest blood test
  4. Patients who have received cytapheresis, blood purification therapy with cytokine adsorbing devices or endotoxin removal therapy between informed consent and enrollment
  5. Patients whose is ≤ 24 hours after enrollment
  6. Patients after resuscitation from cardiac arrest between informed consent and enrollment
  7. Patients tested positive for COVID-19 between informed consent and enrollment

(ARDS caused by COVID-19 cohort)

Inclusion Criteria:

At Informed Consent

  1. Patients tested positive for COVID-19
  2. Patients with ARDS confirmed by the Berlin definition based on the following diagnostic criteria (a)-(d):

    1. Patients within 7 days from invasion or exacerbation of respiratory symptoms or acute onset of ARDS.
    2. Patients with respiratory failure not fully explained by cardiac failure or fluid overload; Need objective assessment (e. g., echo-cardiography) to exclude hydrostatic edema if no risk factor present
    3. Patients with bilateral opacities not fully explained by effusions, lobar/ lung collapse, or nodules on chest X-ray or CT scan
    4. Patients with PaO2/ FiO2 ratio ≤ 300 mmHg (PEEP ≥ 5 cmH2O)
  3. Patients who are intubated and mechanically ventilated
  4. Patients who can be enrolled in the study within 96 hours after initiation of mechanical ventilation
  5. Patients aged ≥ 16 years at informed consent (Signed informed consent form from legally acceptable representative must be available if patient is aged \< 20 years)

At Enrollment

  1. Patients with PaO2/ FiO2 ratio ≥ 50 mmHg and ≤ 200 mmHg (PEEP ≥ 5 cmH2O)
  2. Patients who are intubated and mechanically ventilated
  3. Patients who can be enrolled in the study within 96 hours after initiation of mechanical ventilation

Exclusion Criteria:

At Informed Consent

  1. Patients who are considered to be extremely unlikely to withdraw from mechanical ventilation
  2. Patients who are treated with ECMO or HFOV
  3. Patients with renal dialysis therapy for chronic renal failure
  4. Patients with congestive heart failure (NYHA class IV)
  5. Patients with acuter left ventricular failure
  6. Patients with liver failure (Child-Pugh grade C)
  7. Patients who have burns in excess of 15% total body surface area
  8. Patients after resuscitation from cardiac arrest
  9. Patients with a history of hypersensitivity to the anticoagulants (Heparin or Nafamostat mesylate)
  10. Patients who have received cytapheresis, blood purification therapy with cytokine adsorbing devices or endotoxin removal therapy within 7 days prior to informed consent
  11. Patients with pregnancy or lactating

At Enrollment

  1. Patients who are considered to be extremely unlikely to withdraw from mechanical ventilation
  2. Patients who are treated with ECMO or HFOV after obtaining informed consent prior to enrollment
  3. Patients with platelet count ≤ 50,000 /mm3 by the latest blood test
  4. Patients who have received cytapheresis, blood purification therapy with cytokine adsorbing devices or endotoxin removal therapy between informed consent and enrollment
  5. Patients whose life expectancy is ≤ 24 hours after enrollment
  6. Patients after resuscitation from cardiac arrest between informed consent and enrollment
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    NOA-001 group (ARDS caused by Non-COVID-19 cohort)

    Patients will receive the standard and NOA-001 therapy.

    Device: NOA-001

  • No intervention
    Standard treatment group (ARDS caused by Non-COVID-19 cohort)

    Patients will receive the standard therapy.

  • Experimental
    NOA-001 group (ARDS caused by COVID-19 cohort)

    Patients will receive the standard and NOA-001 therapy.

    Device: NOA-001

Interventions

  • DeviceNOA-001

    NOA-001 will be replaced regularly (at 22 to 24 hours after the initiation of procedure), and will be continuously performed until 168 hours from the enrollment.

06

What researchers measure

Primary outcomes

  1. Ventilator Free Days (VFD, Days alive and ventilator-free)

    VFD is a composite measure of all-cause mortality and the number of days free of mechanical ventilation (VFD) within 28 days.

    Time frame: Day 28

Secondary outcomes

  1. All-cause Mortality

    Fatalities, mortality all-causes

    Time frame: Up to Day 28, 60 and 90

  2. Mortality in ICU

    All-cause mortality for patients who died in Intensive Care Units.

    Time frame: Up to Day 28

  3. Mortality in Hospital

    The number of patients who died in hospital

    Time frame: Up to Day 28

  4. Changes in PaO2/ FiO2 ratio

    Time frame: Up to Day 28

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Jun 2025, 49 months after the start.

Of 273 interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 49 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2021
First posted
Mar 18, 2021
StartActual
May 22, 2021
Primary completionEst.
Jun 30, 2025
CompletionEst.
Sep 4, 2025
Last update
Jul 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04804943
Lead sponsor
Toray Industries, Inc
Responsible party
Sponsor
First posted
Mar 18, 2021
Start date
May 22, 2021
Primary completion
Jun 30, 2025 (estimated)
Completion
Sep 4, 2025 (estimated)
Last update
Jul 9, 2024

Study contacts

NOA-001 Team
Contact
clinical-trials.toray.mb@mail.toray
+81 3 3245 8588

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion